after joining the study, you attend an initial clinic visit.

during this visit, basic health information is recorded and measurements of hair loss are taken using the severity of alopecia tool (SALT) score.

blood samples may be collected to evaluate safety before any medication is given.

based on the study design, you are assigned randomly to receive either ly4005130 (the active drug) or placebo (a substance with no active ingredient).

the assignment is unknown to you and the study staff (double‑blind).

the study medication is administered by intravenous infusion, which means it is delivered directly into a vein using a solution for injection.

the protocol specifies a single infusion; the exact amount is listed as 0 mg in the study documentation, and the infusion is performed under medical supervision.

after the infusion, you return to the clinic for regular follow‑up visits according to the study schedule.

each visit includes evaluation of hair growth using the SALT score, safety checks such as blood tests, and recording of any side effects.

the timing of these visits follows the study calendar, which spans the period from the start of recruitment (31 may 2026) to the end of the study (27 july 2026).

at the end of the study period, a final clinic visit is performed.

the primary outcome is the proportion of participants who achieve a SALT score of 20 or less, indicating significant hair regrowth.

overall safety and any adverse events are summarized before the study concludes.